(AGENPARL) – SILVER SPRING gio 06 aprile 2023 Quinacrine appears on the FDA 503B list of bulk drug substances that may be used in ccompounded drugs. FDA’s review for the 503B Bulks List determined that there is a clinical need for drug products compounded from quinacrine in the treatment of some patients with cutaneous lupus erythematosus.
Fonte/Source: http://www.fda.gov/drugs/human-drug-compounding/compounding-safety-information-quinacrine-hydrochloride